Mandate

Vinge advises industrifonden in connection with pharmalink’s capital raising of sek 96 million

October 08, 2013

Industrifonden and the Norwegian investment company, Investinor have invested a combined total of SEK 79 million in Pharmalink, the pharmaceuticals development company. Private investors have also contributed to the total capital raising of SEK 96 million. The funds will be used to further develop Pharmalink’s product portfolio.

Pharmalink is a pharmaceuticals company which improves and further develops existing pharmaceuticals. The company is currently conducting the Nefecon project for the treatment of inflammation of the kidneys and the Busulipo project for treatment prior to bone marrow transplantation.

Industrifonden has been a stakeholder in Pharmalink since 2004. The Norwegian investment company, Investinor is a new stakeholder.

Vinge partner Johan Larsson advised Industrifonden

Related

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024

Vinge advises Triton in connection with the divestment of Norstat to Nalka Invest

Vinge advises Triton Smaller Mid-Cap Fund I (“Triton”) in connection with the divestment of Norstat, a leading data collector for market research, to Nalka Invest.
April 12, 2024